A

pair of long-acting drugs that would be the first used for preventing migraines may cause a different kind of headache.

Known as CGRP inhibitors, the injectable drugs work by interfering with a substance involved in modifying nerve signals, and recent studies found that two of the medicines reduce the frequency at which migraines appeared. This may be good news for the estimated 38 million migraine sufferers in the U.S., as well as investors, since the market for such drugs will be worth billions of dollars.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.